🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

PARK MEDI WORLD LIMITED PARKHOSPS NSEPHARMA

Healthcare · Medical Care Facilities · India
https://www.parkhospital.in
Company Profile ↓
₹292.10
+97.43% 1Y
Mkt Cap₹12,616.70 Cr
P/E42.52
P/B5.72
52W High₹299.30
52W Low₹143.92
Book Value₹46.81
EPS (TTM)₹6.87

Company Overview

Park Medi World Limited operates a network of hospitals. The company provides cardiac sciences, neurosciences - brain and spine, plastic and cosmetic surgery, general and laparoscopic surgery, renal sciences and kidney transplant, bone, orthopaedics, joint replacement and sports medicine, gastroenterology and surgical gastroenterology, cancer care, bone marrow transplant, iMARS / robot-assisted surgery. It also offers bariatric surgery, anaesthesiology, critical care, chest and respiratory diseases, dental care, dermatology, endocrinology, paediatrics, internal medicine and geriatrics, rheumatology, ENT, ophthalmology, obstetrics and gynaecology, interventional radiology and imaging, psychiatry, pathology and microbiology, paediatric surgery, fertility management, nuclear medicine services. It operates NABH accredited multi-super specialty hospitals under the Park brand name. Park Medi World Limited was founded in 2005 and is headquartered in Gurugram, India.

Why Investors Should Care

Healthy Capital Returns

Return on capital employed stands at 18.1%.

Steady Revenue Expansion

Revenue has grown at a 10.3% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 15.4%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.18.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹1,679.36 Cr (+20.5% YoY); net profit ₹258.12 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +20.5%, earnings +28.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.3%, profit CAGR 5.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.27%
1 Year:20.51%

Compounded Profit Growth

5 Years:5.52%
1 Year:28.01%

Stock Price Performance

1 Year:+97.43%
6 Months:+96.36%
3 Months:+41.92%
1 Month:+7.19%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 95% of range
₹143.92 ₹299.30
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)56.01 · Neutral
Price Performance
1M+7.19%
3M+41.92%
6M+96.36%
1Y+97.43%
Valuation vs Sector

P/E of 42.52 is above the sector median of 39.97 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 10.3% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
42.52
Industry PE
39.97
Forward P/E
28.36
PEG Ratio
-
Book Value
₹46.81
Price to Book
5.72
P/S
7.47
EV/EBITDA
26.06
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
10.27%
Profit 5Y
5.52%
Revenue (YoY)
20.51%
Earnings (YoY)
28.01%

Profitability & Returns

ROCE
18.10%
ROE
12.77%
ROA
9.18%
Profit Margin
15.37%
Op Margin
22.74%
Gross Margin
63.13%
EPS (Latest Qtr)
₹1.64
EPS (TTM)
₹6.87

Balance Sheet & Liquidity

Debt/Equity
0.18
Quick Ratio
2.05
Current Ratio
2.06
Debt
₹364.19 Cr
Total Assets
₹2,813.15 Cr
Current Assets
₹1,087.79 Cr
Working Capital
₹558.89 Cr

Ownership

Promoter Holding
83.94%
Chg in Prom Hold
1.05%
FII / Inst Holding
5.92%
Chg in FII Hold
-0.22%

Financial Snapshot

Enterprise Value
₹12,616.70 Cr
Total Revenue (TTM)
₹1,679.36 Cr
EBITDA
₹475.93 Cr
Free Cash Flow
₹209.41 Cr
Operating Cash Flow
₹329.09 Cr
Shares Outstanding
₹43.19 Cr
Gross Margin
63.13%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 PARKHOSPS PARK MEDI WORLD LIMITED NSEPHARMA 292.10 42.52 ₹12,616.70 Cr 0.00% 18.10% 12.77% 10.27% 5.52%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue 348.13 Cr353.92 Cr410.00 Cr409.97 Cr460.41 Cr
Cost of Revenue 143.32 Cr135.97 Cr-158.72 Cr165.79 Cr
Gross Profit 204.81 Cr217.95 Cr-251.25 Cr294.62 Cr
Operating Expenses 137.03 Cr145.04 Cr297.00 Cr167.14 Cr184.76 Cr
Operating Income 67.78 Cr72.91 Cr98.00 Cr84.11 Cr109.86 Cr
EBITDA 97.56 Cr97.00 Cr113.00 Cr108.51 Cr134.87 Cr
Interest Expense 15.73 Cr15.64 Cr15.00 Cr14.95 Cr13.97 Cr
Pretax Income 66.81 Cr65.83 Cr91.00 Cr78.27 Cr103.39 Cr
Tax Provision 21.16 Cr13.47 Cr12.74 Cr25.42 Cr26.61 Cr
Net Income 45.59 Cr44.84 Cr79.00 Cr50.78 Cr70.86 Cr
Diluted EPS 1.061.041.911.351.64

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 766.00 Cr1,084.00 Cr1,252.38 Cr1,229.06 Cr1,393.57 Cr1,679.36 Cr
Cost of Revenue --411.50 Cr472.88 Cr557.82 Cr619.20 Cr
Gross Profit --840.87 Cr756.18 Cr835.75 Cr1,060.15 Cr
Operating Expenses 457.00 Cr740.00 Cr468.97 Cr486.47 Cr521.66 Cr678.29 Cr
Operating Income 285.00 Cr310.00 Cr371.90 Cr269.72 Cr314.10 Cr381.86 Cr
EBITDA 309.00 Cr345.00 Cr404.74 Cr338.27 Cr403.40 Cr475.93 Cr
Interest Expense 24.00 Cr40.00 Cr49.20 Cr69.53 Cr60.84 Cr58.88 Cr
Pretax Income 265.00 Cr278.00 Cr315.03 Cr218.16 Cr285.67 Cr354.58 Cr
Tax Provision 68.90 Cr77.84 Cr86.84 Cr66.16 Cr70.23 Cr81.03 Cr
Net Income 187.00 Cr199.00 Cr219.67 Cr153.49 Cr201.64 Cr258.12 Cr
Diluted EPS 80.5411.765.093.554.676.87

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 816.00 Cr1,293.00 Cr1,592.82 Cr1,912.10 Cr2,133.70 Cr2,813.15 Cr
Current Assets --818.56 Cr943.02 Cr1,033.66 Cr1,087.79 Cr
Cash & Equivalents --100.05 Cr76.63 Cr103.00 Cr236.85 Cr
Inventory --1.68 Cr2.20 Cr2.54 Cr2.90 Cr
Receivables --576.36 Cr510.96 Cr613.50 Cr593.49 Cr
Total Liabilities --862.85 Cr976.59 Cr1,007.43 Cr708.85 Cr
Current Liabilities --521.38 Cr526.59 Cr556.12 Cr528.90 Cr
Long Term Debt --318.77 Cr391.02 Cr384.25 Cr18.96 Cr
Total Debt 292.00 Cr517.00 Cr575.68 Cr686.71 Cr682.07 Cr364.19 Cr
Total Equity 275.00 Cr457.00 Cr686.56 Cr882.79 Cr1,069.58 Cr2,021.98 Cr
Shares Outstanding --43.19 Cr43.19 Cr43.19 Cr43.19 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 223.00 Cr155.00 Cr195.03 Cr361.44 Cr215.38 Cr329.09 Cr
Investing Cash Flow -233.00 Cr-248.00 Cr-179.63 Cr-254.55 Cr-100.15 Cr-333.45 Cr
Financing Cash Flow 49.00 Cr163.00 Cr1.51 Cr-130.30 Cr-88.86 Cr120.83 Cr
Capital Expenditure -137.00 Cr-91.00 Cr-98.43 Cr-71.45 Cr-145.12 Cr-119.69 Cr
Free Cash Flow 86.00 Cr64.00 Cr96.60 Cr289.98 Cr70.27 Cr209.41 Cr
Net Change in Cash 39.00 Cr70.00 Cr16.91 Cr-23.42 Cr26.38 Cr116.48 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --67.1%61.5%60.0%63.1%
Operating Margin % 37.2%28.6%29.7%21.9%22.5%22.7%
Net Margin % 24.4%18.4%17.5%12.5%14.5%15.4%
ROE % 68.0%43.5%32.0%17.4%18.9%12.8%
ROCE % --34.7%19.5%19.9%16.7%

Shareholding Pattern

Insiders
83.94%
Institutions
5.92%
Public Float
36.84%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PARKHOSPS

Google News Mon, 20 Apr 2026

PARKHOSPS Stock Price and Chart — NSE:PARKHOSPS - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE0xRm9Vb21hRzdOR1RJaC0wLWtPUm9kNlJPVmZCVXdZTUZnbi1ZWVNOM0NMQWRBcEQydWRHbWs2YTE3aGd4TmVxSTBGWVd3U05HT3BDUTRpanp5NTlBRUMw?oc=5" target="_blank">PARKHOSPS Stock Price and Chart — NSE:P…

Google News Mon, 04 May 2026

Park Medi World Ltd | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTFAzaDFCT2EyUnZnVzZMTDhJSFlsOXNCZE80ZTVKMzhIeWY3ODlpeVQ3THBpUnhFSmdDckowdVQyZl9ydm1Xc1E2Y3hJaWxIMGtIb0YzUzJxV1pIU1NPWkFmaDllYVRzTk1WekFkMXc5eU5rdW8?oc=5" target="_blank">Park Medi Wo…

Google News Mon, 15 Jun 2026

17,092,234 Equity Shares of Park Medi World Limited are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com

<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxPNWdzaThHcXYtdFhZZkFyalpMTVZZWktzRmE0N0w2WUhhXzFydXkzN2JudVVHcms3cGxBT2JsOEl0TUd4MXhXSFIzUVRzZG8xR1AyNEEwT1JmLUFKSjc0V3F0SnM5WGdhbWdManJjVWh3VG8xOFgzSUpOWkNHTjY0cFdsQ25DVjVSOHhnT3…

Google News Sat, 11 Jul 2026

Stock To Buy For Long-Term: Nuvama Calls Park Medi World A Buy For Rs 280 Target; 39% Upside Seen - Goodreturns

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNlpwVG5HUlJudlRrcVVGQXYyU0VGTkkycnZvNlVCZDVEMFh3WU9fMDlqNXpxWTBiZDR4SHRablpfR2pnRG5ZLUdqVDByNFRydDgzNmhNUzZ4SGx0N0tuLXVOY2tLMUNvU0ktaEo3eE9XZ3dkWXdEZktIZ3F0N2pVTm1rcU1qU09sdTd5S0…

Google News Wed, 17 Dec 2025

PARKHOSPS Share Price Today - Park Medi World Stock Analysis - Equitypandit

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1Nc3Z3aFRwNlhHQUJuamlyUE5IYlhJd3g5OTEzZVB6dW5mLXpXRnA0Uzh2OUYxNkR6M0ViQV90ZEpfNXZhQVdTTUlJMDV4NHkxbXR4NUxhcEswdllZYXY4?oc=5" target="_blank">PARKHOSPS Share Price Today - Park Medi…

Google News Sun, 14 Dec 2025

Park Medi World IPO Allotment Status: Check GMP, Steps to Verify Status - Groww

<a href="https://news.google.com/rss/articles/CBMiakFVX3lxTE9sOWVrZ25pazBpNExic1F0UzdRNnNmMWNBNV9ueTdQNk4wUGpieUFCZVdGWU85OC1wUnBHaUM2MGhZaGhpTUtiaHpBYmd2UG84QWIxX01CS2c5MFJXNmdmZmlxQkhFbHF5UWc?oc=5" target="_blank">Park Medi World IPO Allo…

PARKHOSPS — Frequently Asked Questions

What is the current share price of PARK MEDI WORLD LIMITED (PARKHOSPS)?

As of 2026-07-15 09:52 IST, PARK MEDI WORLD LIMITED (PARKHOSPS) trades at ₹292.10 on NSE. Its 52-week range is ₹143.92 to ₹299.30.

What is the market capitalisation of PARKHOSPS?

PARK MEDI WORLD LIMITED (PARKHOSPS) has a market capitalisation of ₹12,616.70 Cr on NSE.

What is the P/E ratio of PARKHOSPS?

PARKHOSPS trades at a trailing price-to-earnings (P/E) ratio of 42.52. The industry average P/E is 39.97. Its price-to-book (P/B) ratio is 5.72.

What is the return on equity (ROE) of PARKHOSPS?

PARKHOSPS has a return on equity (ROE) of 12.77%. Its return on capital employed (ROCE) is 18.10%.

Is PARKHOSPS a good stock to buy?

This page provides a data-driven analysis of PARK MEDI WORLD LIMITED (PARKHOSPS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space